STIM
Neuronetics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$2.71
+19.69%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.57
From 52W high−18.03%
Volume5.44M
Market cap$206.11M
P/E (TTM)—
P/S (TTM)1.3x
Div yield—
Key dataNov 4, 2026
Open
$2.57
From 52W high
−18.03%
Volume
5.44M
Market cap
$206.11M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−14.0x
P/E (TTM)
—
RSI (14)
66.5
MomentumView details →
1D Return
+19.69%
YTD Return
+103.75%
SummaryUpdated Jun 1, 2026
Neuronetics, Inc. (NASDAQ:STIM) is a commercial-stage medical technology company founded in 2001 and headquartered in Malvern, Pennsylvania. The company went public in June 2018 and has evolved from a pure medical device manufacturer into a vertically integrated mental health care provider through its 2024 acquisition of Greenbrook TMS. Neuronetics specializes in non-invasive brain stimulation therapies for treating various neurohealth disorders, with a primary focus on depression treatment through its flagship NeuroStar Advanced Therapy System.
Similar companies
Latest newsMore news →
Neuronetics, Inc. reported a quarterly loss of $0.02 per share, compared with a Zacks Investment Research, Inc. Consensus Estimate of a $0.08 loss and a loss of $0.13 per share a year earlier.6h agoNeuronetics announced its financial and operating results for the third quarter of 2026.9h agoNeuronetics announced that it plans to release its third-quarter 2026 financial and operating results before market open on November 4, 2026.14d ago